RYBREVANT FASPROBeyond's analysis on RYBREVANT FASPRO2026-09-15 — Johnson & Johnson's subcutaneous regimen for NSCLC shows strong safety profile at WCLC 2026Recent news mentioning RYBREVANT FASPRO2026-09-15 — RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026Appears alongsideLAZCLUZEWCLCBrowse the full archive →